[{"id":"89c75df9-9804-4899-a467-168d5893aeb8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05316116","created_at":"2022-04-07T13:56:37.378Z","updated_at":"2025-02-25T17:01:47.416Z","phase":"Phase 1","brief_title":"Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)","source_id_and_acronym":"NCT05316116","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" CD8 • B3GAT1","pipe":"","alterations":" ","tags":["CD8 • B3GAT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Sylvant (siltuximab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 02/15/2023","start_date":" 02/15/2023","primary_txt":" Primary completion: 11/17/2026","primary_completion_date":" 11/17/2026","study_txt":" Completion: 11/17/2027","study_completion_date":" 11/17/2027","last_update_posted":"2025-02-03"},{"id":"7a2918a3-5cca-4af4-9ede-643ba7496c81","acronym":"","url":"https://clinicaltrials.gov/study/NCT01745588","created_at":"2021-01-18T07:39:01.782Z","updated_at":"2025-02-25T14:33:53.694Z","phase":"Phase 2","brief_title":"Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT01745588","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dexamethasone • pomalidomide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 12/01/2012","start_date":" 12/01/2012","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-07-03"},{"id":"8deded4a-9926-4f1a-a26a-90e378ae94dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04577755","created_at":"2023-11-14T19:14:53.297Z","updated_at":"2024-07-02T16:35:08.364Z","phase":"Phase 2","brief_title":"Pomalidomide Treatment in Patients With Kaposi Sarcoma","source_id_and_acronym":"NCT04577755","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pomalidomide"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 03/18/2022","start_date":" 03/18/2022","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-04-22"},{"id":"dc0579d6-d285-4c4f-a4da-1f44bfe4d346","acronym":"","url":"https://clinicaltrials.gov/study/NCT06069024","created_at":"2023-10-05T16:11:22.043Z","updated_at":"2024-07-02T16:35:10.669Z","phase":"","brief_title":"Population Pharmacokinetic Study Based on Quantitative Pharmacology in Patients With Lenalidomide","source_id_and_acronym":"NCT06069024","lead_sponsor":"Qianfoshan Hospital","biomarkers":" ABCB1","pipe":"","alterations":" ","tags":["ABCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 10/15/2021","start_date":" 10/15/2021","primary_txt":" Primary completion: 05/31/2023","primary_completion_date":" 05/31/2023","study_txt":" Completion: 05/31/2023","study_completion_date":" 05/31/2023","last_update_posted":"2024-04-09"},{"id":"2fd1f36d-538c-4925-82be-67b0b08c4340","acronym":"","url":"https://clinicaltrials.gov/study/NCT04301076","created_at":"2021-01-18T20:51:47.723Z","updated_at":"2024-07-02T16:35:16.189Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (\"EPOCH\") for Adult T-Cell Leukemia-Lymphoma (ATL)","source_id_and_acronym":"NCT04301076","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4 • CD2","pipe":"","alterations":" ","tags":["CD4 • CD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/31/2021","start_date":" 08/31/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-06"},{"id":"df710e35-6fee-433d-8b5e-2a0f0b481289","acronym":"","url":"https://clinicaltrials.gov/study/NCT05846880","created_at":"2023-05-06T14:04:17.467Z","updated_at":"2024-07-02T16:35:19.162Z","phase":"Phase 1","brief_title":"VitD3 Supplementation in Patients With Multiple Myeloma","source_id_and_acronym":"NCT05846880","lead_sponsor":"Amany Keruakous, MD, MS.","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 05/01/2028","primary_completion_date":" 05/01/2028","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2024-02-15"},{"id":"92d236cb-41f3-4477-91bc-450b492b95a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01054196","created_at":"2021-01-18T04:08:59.899Z","updated_at":"2025-02-25T14:31:39.955Z","phase":"Phase 1/2","brief_title":"Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study","source_id_and_acronym":"NCT01054196","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • melphalan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 08/01/2010","start_date":" 08/01/2010","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-02-01"},{"id":"bf2c24bb-0980-48a4-95ed-efc1d3846155","acronym":"","url":"https://clinicaltrials.gov/study/NCT02561273","created_at":"2021-01-18T12:24:07.010Z","updated_at":"2024-07-02T16:35:26.335Z","phase":"Phase 1/2","brief_title":"Combination Chemotherapy \u0026 Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT02561273","lead_sponsor":"University of Nebraska","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 09/28/2015","start_date":" 09/28/2015","primary_txt":" Primary completion: 11/01/2019","primary_completion_date":" 11/01/2019","study_txt":" Completion: 11/01/2020","study_completion_date":" 11/01/2020","last_update_posted":"2023-12-13"},{"id":"21b0c328-ef65-489f-97f4-6f64457182a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03315026","created_at":"2021-01-18T16:22:17.873Z","updated_at":"2024-07-02T16:35:30.682Z","phase":"Phase 2","brief_title":"Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis","source_id_and_acronym":"NCT03315026","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Sylvant (siltuximab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/14/2017","start_date":" 12/14/2017","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-11-02"},{"id":"5766f363-23d7-4ddf-aa99-822a48d173b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02185820","created_at":"2021-02-04T20:52:56.667Z","updated_at":"2024-07-02T16:35:44.252Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)","source_id_and_acronym":"NCT02185820","lead_sponsor":"European Myeloma Network","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carfilzomib • dexamethasone • pomalidomide"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 06/01/2014","start_date":" 06/01/2014","primary_txt":" Primary completion: 07/01/2015","primary_completion_date":" 07/01/2015","study_txt":" Completion: 01/01/2023","study_completion_date":" 01/01/2023","last_update_posted":"2023-06-30"},{"id":"5549ff6d-d0c0-4524-812c-e784acd2dec2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04305444","created_at":"2021-01-18T20:52:47.509Z","updated_at":"2024-07-02T16:35:49.171Z","phase":"Phase 2","brief_title":"Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas","source_id_and_acronym":"NCT04305444","lead_sponsor":"Zhejiang DTRM Biopharma","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pomalidomide • DTRM-555 • DTRMWXHS-12"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 04/24/2020","start_date":" 04/24/2020","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2023-05-02"},{"id":"a86eae23-5fcb-4a8b-a5e6-a0ef3b33f450","acronym":"","url":"https://clinicaltrials.gov/study/NCT02213913","created_at":"2021-01-18T10:22:23.451Z","updated_at":"2024-07-02T16:35:49.349Z","phase":"Phase 1/2","brief_title":"Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas","source_id_and_acronym":"NCT02213913","lead_sponsor":"University of Chicago","biomarkers":" MYC • BCL2 • CD20 • BCL6 • IRF4 • MME","pipe":" | ","alterations":" BCL2 positive","tags":["MYC • BCL2 • CD20 • BCL6 • IRF4 • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • melphalan • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 07/29/2014","start_date":" 07/29/2014","primary_txt":" Primary completion: 07/29/2023","primary_completion_date":" 07/29/2023","study_txt":" Completion: 07/29/2023","study_completion_date":" 07/29/2023","last_update_posted":"2023-04-28"},{"id":"819ddf6a-92fd-4e69-a9c7-80cd6ae4f183","acronym":"SILTUXILAM","url":"https://clinicaltrials.gov/study/NCT05697510","created_at":"2023-01-26T16:02:10.196Z","updated_at":"2024-07-02T16:35:51.296Z","phase":"Phase 1","brief_title":"Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: SILTUXILAM","source_id_and_acronym":"NCT05697510 - SILTUXILAM","lead_sponsor":"Nantes University Hospital","biomarkers":" IL6","pipe":"","alterations":" ","tags":["IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • Sylvant (siltuximab)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 03/16/2023","start_date":" 03/16/2023","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2023-04-06"},{"id":"52f8a9a1-95f2-46c1-9a42-1380744675d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02126553","created_at":"2021-01-18T09:51:35.162Z","updated_at":"2024-07-02T16:36:00.548Z","phase":"Phase 2","brief_title":"Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission","source_id_and_acronym":"NCT02126553","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 11/13/2014","start_date":" 11/13/2014","primary_txt":" Primary completion: 11/30/2021","primary_completion_date":" 11/30/2021","study_txt":" Completion: 11/30/2021","study_completion_date":" 11/30/2021","last_update_posted":"2022-11-11"},{"id":"609b62e0-5459-4e6f-b8b3-1e6b3e397774","acronym":"","url":"https://clinicaltrials.gov/study/NCT01495598","created_at":"2022-11-05T15:11:43.110Z","updated_at":"2024-07-02T16:36:01.485Z","phase":"Phase 1/2","brief_title":"Pomalidomide for Kaposi Sarcoma in People With or Without HIV","source_id_and_acronym":"NCT01495598","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pomalidomide"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 01/10/2012","start_date":" 01/10/2012","primary_txt":" Primary completion: 05/17/2022","primary_completion_date":" 05/17/2022","study_txt":" Completion: 05/17/2022","study_completion_date":" 05/17/2022","last_update_posted":"2022-11-01"},{"id":"3a0c49c1-727b-492b-bc54-7034bb716618","acronym":"KMM1911","url":"https://clinicaltrials.gov/study/NCT05497102","created_at":"2022-08-15T11:10:45.029Z","updated_at":"2024-07-02T16:36:05.577Z","phase":"Phase 2","brief_title":"Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT","source_id_and_acronym":"NCT05497102 - KMM1911","lead_sponsor":"Samsung Medical Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • carfilzomib • dexamethasone • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 11/08/2021","start_date":" 11/08/2021","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2022-08-12"},{"id":"2fb657ac-eed2-45a0-bd11-acbeb884bff1","acronym":"SPACE","url":"https://clinicaltrials.gov/study/NCT03113942","created_at":"2021-01-29T07:14:31.583Z","updated_at":"2024-07-02T16:36:14.293Z","phase":"Phase 2","brief_title":"Study of Pomalidomide in Anal Cancer Precursors","source_id_and_acronym":"NCT03113942 - SPACE","lead_sponsor":"Kirby Institute","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pomalidomide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 06/14/2017","start_date":" 06/14/2017","primary_txt":" Primary completion: 03/31/2019","primary_completion_date":" 03/31/2019","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2022-03-31"},{"id":"019e5c1f-7cc6-4bf5-9b54-11b80b290251","acronym":"","url":"https://clinicaltrials.gov/study/NCT03375567","created_at":"2021-01-29T07:16:40.130Z","updated_at":"2024-07-02T16:36:16.671Z","phase":"","brief_title":"Global Response Assessment by Advanced Imaging and Myeloma Lesion Biopsies During Induction Therapy of Multiple Myeloma With Carfilzomib Lenalidomide Dexamethasone","source_id_and_acronym":"NCT03375567","lead_sponsor":"Yale University","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • carfilzomib • dexamethasone"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 06/04/2018","start_date":" 06/04/2018","primary_txt":" Primary completion: 01/14/2022","primary_completion_date":" 01/14/2022","study_txt":" Completion: 01/14/2022","study_completion_date":" 01/14/2022","last_update_posted":"2022-02-24"},{"id":"d20a1a1c-6571-4f80-9551-ee94421c97f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01057121","created_at":"2021-01-29T07:00:24.457Z","updated_at":"2024-07-02T16:36:17.455Z","phase":"Phase 1/2","brief_title":"Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma","source_id_and_acronym":"NCT01057121","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 08/27/2010","start_date":" 08/27/2010","primary_txt":" Primary completion: 08/04/2014","primary_completion_date":" 08/04/2014","study_txt":" Completion: 08/04/2014","study_completion_date":" 08/04/2014","last_update_posted":"2022-02-08"},{"id":"4ce7a3df-8c27-474f-af59-9ed067c83069","acronym":"","url":"https://clinicaltrials.gov/study/NCT01556776","created_at":"2021-01-18T06:35:30.682Z","updated_at":"2025-02-25T14:33:24.033Z","phase":"Phase 3","brief_title":"A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy","source_id_and_acronym":"NCT01556776","lead_sponsor":"German CLL Study Group","biomarkers":" TP53 • IGH","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide"],"overall_status":"Completed","enrollment":" Enrollment 89","initiation":"Initiation: 07/20/2012","start_date":" 07/20/2012","primary_txt":" Primary completion: 03/01/2016","primary_completion_date":" 03/01/2016","study_txt":" Completion: 01/14/2021","study_completion_date":" 01/14/2021","last_update_posted":"2022-01-05"},{"id":"775c2a76-908f-4588-90eb-00f72be8acce","acronym":"STAMINA","url":"https://clinicaltrials.gov/study/NCT01109004","created_at":"2021-01-18T04:23:28.887Z","updated_at":"2024-07-02T16:36:19.703Z","phase":"Phase 3","brief_title":"Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)","source_id_and_acronym":"NCT01109004 - STAMINA","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • bortezomib • melphalan"],"overall_status":"Completed","enrollment":" Enrollment 758","initiation":"Initiation: 05/01/2010","start_date":" 05/01/2010","primary_txt":" Primary completion: 01/15/2017","primary_completion_date":" 01/15/2017","study_txt":" Completion: 03/03/2018","study_completion_date":" 03/03/2018","last_update_posted":"2021-12-09"},{"id":"b3557694-13d2-410d-9e56-588a1d4c4b25","acronym":"","url":"https://clinicaltrials.gov/study/NCT05105412","created_at":"2021-11-03T12:53:04.761Z","updated_at":"2024-07-02T16:36:21.539Z","phase":"Phase 1/2","brief_title":"Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas","source_id_and_acronym":"NCT05105412","lead_sponsor":"National Health Research Institutes, Taiwan","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • lenalidomide"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 10/31/2021","start_date":" 10/31/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2021-11-03"},{"id":"f60e6b64-d4a6-4c87-b498-d69b76e6150f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01402284","created_at":"2021-01-18T05:45:42.710Z","updated_at":"2025-02-25T14:32:59.232Z","phase":"Phase 2","brief_title":"Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients","source_id_and_acronym":"NCT01402284","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SDC1","pipe":"","alterations":" ","tags":["SDC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • carfilzomib • dexamethasone"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 07/21/2011","start_date":" 07/21/2011","primary_txt":" Primary completion: 07/10/2016","primary_completion_date":" 07/10/2016","study_txt":" Completion: 09/24/2020","study_completion_date":" 09/24/2020","last_update_posted":"2021-03-02"},{"id":"0b9ef04f-8344-4716-abd0-e6c22965b621","acronym":"","url":"https://clinicaltrials.gov/study/NCT00866970","created_at":"2021-01-18T03:18:29.207Z","updated_at":"2024-07-02T16:36:43.424Z","phase":"Phase 2","brief_title":"Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia","source_id_and_acronym":"NCT00866970","lead_sponsor":"CSL Behring","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"],"overall_status":"Completed","enrollment":" Enrollment 124","initiation":"Initiation: 09/01/2008","start_date":" 09/01/2008","primary_txt":" Primary completion: 08/01/2009","primary_completion_date":" 08/01/2009","study_txt":" Completion: 12/01/2009","study_completion_date":" 12/01/2009","last_update_posted":"2020-07-09"}]